Screening, staging, and beta cell function preservation strategies in patients with type 1 DM
https://doi.org/10.31549/2542-1174-2025-9-3-80-95
Abstract
This literature review includes an analysis of data from epidemiological studies, meta-analyses, and scientifi c publications on type 1 DM (T1DM). The results of studies assessing the prevalence and incidence of T1DM in various regions of the world, including Russia, are considered. A widespread increase in these indicators in all age groups over the past 10 years was found. An analysis of data on genetic and environmental risk factors for the development of T1DM, including maternal age, obesity, infections, and vitamin D defi ciency is presented. A classifi cation of T1DM stages is considered, refl ecting the continuum of disease development from the appearance of autoantibodies to clinical symptoms. The emphasis is on the preclinical stages of T1DM and the importance of their early diagnosis for potential prevention and delay of disease progression. The need for an integrated approach to the study of T1DM, taking into account the genetic, environmental, and immunological aspects of the disease, is emphasized. Knowledge of risk factors and stages of development of T1DM allows us to develop strategies for early diagnosis and prevention aimed at delay in the progression of the autoimmune process and development of clinical manifestations of T1DM.
About the Authors
L. A. Ruyatkina
Novosibirsk State Medical University
Russian Federation
Russian Federation
Lyudmila A. Ruyatkina – Dr. Sci. (Med.), Professor, Department of Emergency Therapy with Endocrinology and Occupational Pathology
52, Krasny prosp., Novosibirsk, 630091
V. M. Anmut
Novosibirsk State Medical University
Russian Federation
Russian Federation
Victoria M. Anmut – Clinical Resident, Department of Emergency Therapy with Endocrinology and Occupational Pathology
52, Krasny prosp., Novosibirsk, 630091
M. A. Kovarenko
Novosibirsk State Medical University
Russian Federation
Russian Federation
Margarita A. Kovarenko – Cand. Sci. (Med.), Associate Professor, Department of Pediatrics (Faculty of Advanced Training and Professional Training of Physicians)
52, Krasny prosp., Novosibirsk, 630091
References
1. Akil A.A., Yassin E., Al-Maraghi A. et al. Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era. J. Transl. Med. 2021;19(1):137. DOI: 10.1186/s12967-021-02778-6.
2. Fanaropoulou N.M., Tsatsani G.C., Koufakis T., Kotsa K. Teplizumab: promises and challenges of a recently approved monoclonal antibody for the prevention of type 1 diabetes or preservation of residual beta cell function. Expert Rev. Clin. Immunol. 2024;20(2):185- 196. DOI: 10.1080/1744666X.2023.2281990.
3. So M., Speake C., Steck A.K. et al. Advances in type 1 diabetes prediction using islet autoantibodies: beyond a simple count. Endocr. Rev. 2021;42(5):584-604. DOI: 10.1210/endrev/bnab013.
4. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classifi cation of Diabetes: Standards of Care in Diabetes–2024. Diabetes Care. 2024;47(Suppl 1):S20-S42. DOI: 10.2337/dc24-S002.
5. Haller M.J., Bell K.J., Besser R.E.J. et al. ISPAD Clinical Practice Consensus Guidelines 2024: Screening, staging, and strategies to preserve beta-cell function in children and adolescents with type 1 diabetes. Horm. Res. Paediatr. 2024;97(6):529-545. DOI: 10.1159/000543035.
6. Schatz D.A., Bingley P.J. Update on major trials for the prevention of type 1 DM: the American Diabetes Prevention Trial (DPT-1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT). J. Pediatr. Endocrinol. Metab. 2001;14(Suppl 1):619-622. DOI: 10.1515/jpem.2001.14.s1.619.
7. Laptev D.N., Bezlepkina O.V., Sheshko E.L. et al. Main epidemiological indicators of type 1 diabetus mellitus in children in the Russian Federation for 2014–2023. Problems of Endocrinology. 2024;70(5):76-83. DOI: 10.14341/probl13515. (In Russ.)
8. Patterson C.C., Harjutsalo V., Rosenbauer J. et al. Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989–2013: a multicentre prospective registration study. Diabetologia. 2019;62(3):408-417. DOI: 10.1007/s00125-018-4763-3.
9. Insel R.A., Dunne J.L., Atkinson M.A. et al. Staging presymptomatic type 1 diabetes: a scientifi c statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964- 1974. DOI: 10.2337/dc15-1419.
10. Li Y., Qian K., Wu D. et al. Incidence of childhood type 1 diabetes in Beijing during 2011–2020 and predicted incidence for 2025–2035: a multicenter, hospitalization-based study. Diabetes Ther. 2023;14(3):519- 529. DOI: 10.1007/s13300-023-01367-8
11. Knip M. Type 1 diabetes in Finland: past, present, and future. Lancet Diabetes Endocrinol. 2021;9(5):259- 260. DOI: 10.1016/S2213-8587(21)00074-7.
12. Hussein S., Bandarian F., Salehi N. et al. The eff ect of vitamin D defi ciency on immune-related hub genes: a network analysis associated with type 1 diabetes. Cureus. 2024;16(9):e68611. DOI: 10.7759/cureus.68611.
13. Hippich M., Beyerlein A., Hagopian W.A. et al.; TEDDY Study Group; Teddy Study Group. Genetic contribution to the divergence in type 1 diabetes risk between children from the general population and children from aff ected families. Diabetes. 2019;68(4):847-857. DOI: 10.2337/db18-0882.
14. Redondo M.J., Gignoux C.R., Dabelea D. et al. Type 1 diabetes in diverse ancestries and the use of genetic risk scores. Lancet Diabetes Endocrinol. 2022;10(8):597- 608. DOI: 10.1016/S2213-8587(22)00159-0.
15. Norris J.M., Johnson R.K., Stene L.C. Type 1 diabetesearly life origins and changing epidemiology. Lancet Diabetes Endocrinol. 2020;8(3):226-238. DOI: 10.1016/S2213-8587(19)30412-7.
16. Cardwell C.R., Stene L.C., Joner G. et al. Maternal age at birth and childhood type 1 diabetes: a pooled analysis of 30 observational studies. Diabetes. 2010;59(2):486- 494. DOI: 10.2337/db09-1166.
17. Censin J.C., Nowak C., Cooper N. et al. Childhood adiposity and risk of type 1 diabetes: A Mendelian randomization study. PLoS Med. 2017;14(8):e1002362. DOI: 10.1371/journal.pmed.1002362.
18. Rodriguez-Calvo T. Enteroviral infections as a trigger for type 1 diabetes. Curr. Diab. Rep. 2018;18(11):106. DOI: 10.1007/s11892-018-1077-2.
19. Karavanaki K., Rodolaki K., Soldatou A. et al. Covid-19 infection in children and adolescents and its association with type 1 DM (T1d) presentation and management. Endocrine. 2023;80(2):237-252. DOI: 10.1007/s12020-022-03266-7.
20. Li C., Fu J., Ye Y. et al. The impact of vitamin D on the etiopathogenesis and the progression of type 1 and type 2 diabetes in children and adults. Front. Endocrinol. (Lausanne). 2024;15:1360525. DOI: 10.3389/fendo.2024.1360525.
21. Klenczar-Kciuk K.M., Seget S., Adamczyk P., JaroszChobot P. Vitamin D defi ciency is common among Polish children with newly diagnosed type 1 DM. Endokrynol. Pol. 2025;76(1):59-65. DOI: 10.5603/ ep.100801.
22. Joshi K., Harris M., Cotterill A. et al. Continuous glucose monitoring has an increasing role in presymptomatic type 1 diabetes: advantages, limitations, and comparisons with laboratory-based testing. Clin. Chem. Lab. Med. 2023;62(1):41-49. DOI: 10.1515/cclm-2023-0234.
23. Sims E.K., Besser R.E.J., Dayan C. et al.; NIDDK Type 1 Diabetes TrialNet Study Group. Screening for type 1 diabetes in the general population: A status report and perspective. Diabetes. 2022;71(4):610-623. DOI: 10.2337/dbi20-0054.
24. Besser R.E.J., Ng S.M., Gregory J.W. et al. General population screening for childhood type 1 diabetes: is it time for a UK strategy? Arch. Dis. Child. 2022;107(9):790- 795. DOI: 10.1136/archdischild-2021-321864.
25. Sherwani S.I., Khan H.A., Ekhzaimy A. et al. Signifi cance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomark. Insights. 2016;11:95-104. DOI: 10.4137/BMI.S38440.
26. Bonifacio E., Weiß A., Winkler C. et al.; TEDDY Study Group. An age-related exponential decline in the risk of multiple islet autoantibody seroconversion during childhood. Diabetes Care. 2021;44(10):2260-2268. DOI: 10.2337/dc20-2122.
27. Ghalwash M., Dunne J.L., Lundgren M. et al.; Type 1 Diabetes Intelligence Study Group. Two-age isletautoantibody screening for childhood type 1 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol. 2022;10(8):589-596. DOI: 10.1016/S2213-8587(22)00141-3.
28. Ghalwash M., Anand V., Lou O. et al.; Type 1 Diabetes Intelligence Study Group. Islet autoantibody screening in at-risk adolescents to predict type 1 diabetes until young adulthood: a prospective cohort study. Lancet Child Adolesc. Health. 2023;7(4):261-268. DOI: 10.1016/S2352-4642(22)00350-9.
29. Vehik K., Bonifacio E., Lernmark Å. et al.; TEDDY Study Group. Hierarchical order of distinct autoantibody spreading and progression to type 1 diabetes in the TEDDY Study. Diabetes Care. 2020;43(9):2066- 2073. DOI: 10.2337/dc19-2547.
30. Frohnert B.I., Ghalwash M., Li Y. et al.; T1DI Study Group. Refining the definition of stage 1 type 1 diabetes: an ontology-driven analysis of the heterogeneity of multiple islet autoimmunity. Diabetes Care. 2023;46(10):1753-1761. DOI: 10.2337/dc22-1960.
31. Phillip M., Achenbach P., Addala A. et al. Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetes Care. 2024;47(8):1276-1298. DOI: 10.2337/dci24-0042.
32. Thakkar S., Chopra A., Nagendra L. et al. Teplizumab in type 1 DM: an updated review. touchREV Endocrinol. 2023;19(2):22-30. DOI: 10.17925/EE.2023.19.2.7.
33. Laptev D.N., Dedov I.I. Towards prevention of type 1 diabetes: FDA approved fi rst drug with potential to delay clinical stage of disease. Diabetus Mellitus. 2022;25(6):576-579. DOI: 10.14341/DM12988. (In Russ.)
34. Keam S.J. Teplizumab: fi rst approval. Drugs. 2023;83(5):439-445. DOI: 10.1007/s40265-023- 01847-y.
35. Ramos E.L., Dayan C.M., Chatenoud L. et al.; PROTECT Study Investigators. Teplizumab and β-cell function in newly diagnosed type 1 diabetes. N. Engl. J. Med. 2023;389(23):2151-2161. DOI: 10.1056/NEJMoa2308743.
36. Herold K.C., Gitelman S.E., Gottlieb P.A. et al. Teplizumab: a disease-modifying therapy for type 1 diabetes that preserves β-cell function. Diabetes Care. 2023;46(10):1848-1856. DOI: 10.2337/dc23-0675.
37. Sims E.K., Bundy B.N., Stier K. et al.; Type 1 Diabetes TrialNet Study Group. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci. Transl. Med. 2021;13(583):eabc8980. DOI: 10.1126/scitranslmed.abc8980.
Review
For citations:
Ruyatkina L.A., Anmut V.M., Kovarenko M.A. Screening, staging, and beta cell function preservation strategies in patients with type 1 DM. Journal of Siberian Medical Sciences. 2025;(3):80-95. (In Russ.) https://doi.org/10.31549/2542-1174-2025-9-3-80-95
Views:
4
Email this article 